Lurasidone (lurasidone HCl) is a novel psychotropic agent that is being developed as a potential new antipsychotic treatment for patients with schizophrenia. Switching between antipsychotic medications is common in the treatment of schizophrenia. The current study is designed to evaluate the effectiveness, safety, and tolerability of switching clinically stable, but symptomatic outpatients with schizophrenia or schizoaffective disorder from their preswitch antipsychotic medication to lurasidone, over a period of 6 weeks.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
244
Lurasidone tablets, 40 mg/daily, 80 mg/daily, 120 mg/daily for 6 weeks
K and S Professional Research Services
Little Rock, Arkansas, United States
Synergy Clinical Research of Escondido
Escondido, California, United States
Collaborative Neuroscience Network, Inc.
Garden Grove, California, United States
Pacific Research Partners, LLC
Oakland, California, United States
California Clinical Trials
Paramount, California, United States
Time to Relapse of Psychotic Symptoms During 6 Weeks
Relapse is defined as any occurrence of: * Insufficient clinical response * Exacerbation of underlying disease * Discontinuation due to an adverse event
Time frame: 6 Weeks
Tolerability and Safety
Number of participants with Treatment Emergent Adverse Events and Serious Adverse Events
Time frame: 6 Weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Pasadena Research Institute
Pasadena, California, United States
California Neuropsychopharmacology Clinical Research Institute (CNRI), LLC
Pico Rivera, California, United States
California Neuropsychopharmacology Clinical Research Institute (CNRI)
San Diego, California, United States
University of California San Diego Medical Center
San Diego, California, United States
Collaborative Neuroscience Network, South Bay
Torrance, California, United States
...and 17 more locations